Text Size

Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by Office of Rare Diseases (ORD).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
University of Pennsylvania
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00006060
First received: July 5, 2000
Last updated: March 10, 2009
Last verified: March 2009
History of Changes
  Purpose

OBJECTIVES: I. Determine by quantitative magnetic resonance imaging measurements the change in the total volume of brain parenchyma as well as its gray and white matter, T2 and enhanced T1 lesion volume, and the magnetization transfer ratio histogram parameters, and correlate these measurements with clinical measures of disability in patients with multiple sclerosis.

II. Measure the quantity of whole brain N-acetylaspartate in patients with multiple sclerosis and compare these values to those from age matched controls.

III. Determine the correlation between specific neuropsychological tests which assess global cognitive functioning and the quantitative measurements taken in these patients in this study.


Condition Intervention
Multiple Sclerosis
 Drug: standard gadolinium contrast

Study Type: Observational

Resource links provided by NLM:

Drug Information available for: Gadolinium
U.S. FDA Resources

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment: 100
Study Start Date: April 1999
Detailed Description:

PROTOCOL OUTLINE:

Patients undergo magnetic resonance imaging and spectroscopy with standard gadolinium contrast followed by neuropsychological testing every 6 months for 5 years. An equal number of age and sex matched healthy patients act as a control group and undergo magnetic resonance imaging and spectroscopy without standard gadolinium contrast every 6 months for 5 years.

  Eligibility

Ages Eligible for Study:   20 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Diagnosis of multiple sclerosis Relapsing-remitting defined as 2 exacerbations and a worsening of neurologic function over 1 day followed by at least 30 days of no progression OR Secondary-progressive defined as increase of at least 1.0 unit on Expanded Disability Status Scale (EDSS) in past 2 years with or without exacerbations

--Prior/Concurrent Therapy--

  • Biologic therapy: Prior interferon beta 1A, 1B, or glatiramer acetate No concurrent interferon beta 1A, 1B, or glatiramer acetate
  • Endocrine therapy: Concurrent oral and IV corticosteroids allowed

--Patient Characteristics--

  • Performance status: EDSS no greater than 7.0
  • Hematopoietic: No hematologic dysfunction including hemolytic anemia
  • Hepatic: No hepatic dysfunction
  • Renal: No renal dysfunction
  • Cardiovascular: No cardiac pacemaker
  • Other: Not pregnant or nursing Negative pregnancy test No intracranial clips, metal implants, or external clips within 10 mm of head No metal in eyes No known gadolinium texaphyrin allergy No known claustrophobia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006060

Contacts
Contact: Robert I. Grossman, MD 212-263-3269

Locations
United States, New York
New York University Medical Center Recruiting
New York, New York, United States, 10016
Contact: Lois J. Mannon, BSRT, (MR) (R) CCRC     212-263-3783     lois.mannon@med.nyu.edu    
Principal Investigator: Robert I. Grossman, MD            
Sponsors and Collaborators
National Center for Research Resources (NCRR)
University of Pennsylvania
Investigators
Study Chair: Robert I. Grossman, MD New York University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00006060     History of Changes
Other Study ID Numbers: 199/15245, UPSM-704-0, UPSM-070300, UPSM-NS-29029
Study First Received: July 5, 2000
Last Updated: March 10, 2009
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
multiple sclerosis
neurologic and psychiatric disorders
rare disease

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
 Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on June 18, 2013